Not Yet RecruitingNot Applicable

Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health

China40 participantsStarted 2025-03-10

Plain-language summary

Evaluate the effectiveness and safety of Ligilactobacillus salivarius LS97 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willing to undergo 3 follow-up visits during the intervention period
✓. Be willing to provide blood, urine and stool samples 2 times during the intervention period
✓. Good eyesight, can read and write, can wear glasses
✓. Have good hearing and be able to hear and understand all instructions during the intervention

Exclusion criteria

✕. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
✕. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia)
✕. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia psychosis, bipolar disorder
✕. Take medication for depression or low mood
✕. Internal organ failure (heart, liver or kidney failure, etc.)
✕. Have received radiation or chemotherapy in the past
✕. have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
✕. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past

What they're measuring

Change in the composition of fecal microbiota before and after intervention.

Timeframe: Week 0 and Week 8

Trial details

NCT IDNCT06886724

SponsorWecare Probiotics Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-30

Contact for this trial

Fei Xu

13671979116 xu.fei@haut.edu.cn

View on ClinicalTrials.gov More Intestinal and Lmmune Function Lmproved trials